Fundamental Analysis of LANTERN PHARMA INC(NASDAQ:LTRN) stock

Fundamental Rating

Taking everything into account, LTRN scores 3 out of 10 in our fundamental rating. LTRN was compared to 564 industry peers in the Biotechnology industry. While LTRN has a great health rating, there are worries on its profitability. LTRN does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

LTRN had negative earnings in the past year.

LTRN had a negative operating cash flow in the past year.

In the past 5 years LTRN always reported negative net income.

In the past 5 years LTRN always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -63.02%, LTRN is not doing good in the industry: 61.76% of the companies in the same industry are doing better.

LTRN's Return On Equity of -71.78% is in line compared to the rest of the industry. LTRN outperforms 56.01% of its industry peers.

		Industry Rank	Sector Rank
ROA	-63.02%
ROE	-71.78%
ROIC	N/A

ROA(3y)-25.84%

ROA(5y)-55.3%

ROE(3y)-27.24%

ROE(5y)-74.05%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LTRN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for LTRN has been reduced compared to 1 year ago.

The number of shares outstanding for LTRN has been increased compared to 5 years ago.

There is no outstanding debt for LTRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

LTRN has an Altman-Z score of 2.04. This is not the best score and indicates that LTRN is in the grey zone with still only limited risk for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 2.04, LTRN is in the better half of the industry, outperforming 70.56% of the companies in the same industry.

LTRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.04

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 8.31 indicates that LTRN has no problem at all paying its short term obligations.

The Current ratio of LTRN (8.31) is better than 73.79% of its industry peers.

A Quick Ratio of 8.31 indicates that LTRN has no problem at all paying its short term obligations.

The Quick ratio of LTRN (8.31) is better than 73.97% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.31
Quick Ratio	8.31

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for LTRN have decreased strongly by -27.14% in the last year.

EPS 1Y (TTM)-27.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-44.83%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

LTRN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.10% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-30.95%

EPS Next 2Y-13.22%

EPS Next 3Y6.69%

EPS Next 5Y8.1%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LTRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LTRN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-13.22%

EPS Next 3Y6.69%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for LTRN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LANTERN PHARMA INC

NASDAQ:LTRN (1/3/2025, 8:00:01 PM)

3.74

+0.44 (+13.33%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-07 2024-11-07/amc

Earnings (Next)N/A N/A

Inst Owners23.85%

Inst Owner Change2.8%

Ins Owners0.39%

Ins Owner Change0.26%

Market Cap40.32M

Analysts82.86

Price Target22.44 (500%)

Short Float %2.21%

Short Ratio3.17

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)22.24%

Min EPS beat(2)18%

Max EPS beat(2)26.47%

EPS beat(4)3

Avg EPS beat(4)8.15%

Min EPS beat(4)-16.28%

Max EPS beat(4)26.47%

EPS beat(8)7

Avg EPS beat(8)16.55%

EPS beat(12)10

Avg EPS beat(12)17.16%

EPS beat(16)12

Avg EPS beat(16)12.85%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)15%

EPS NY rev (1m)0%

EPS NY rev (3m)10.38%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.52
P/tB	1.52
EV/EBITDA	N/A

EPS(TTM)-1.78

EYN/A

EPS(NY)-1.9

Fwd EYN/A

FCF(TTM)-1.6

FCFYN/A

OCF(TTM)-1.6

OCFYN/A

SpS0

BVpS2.47

TBVpS2.47

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-63.02%
ROE	-71.78%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-25.84%

ROA(5y)-55.3%

ROE(3y)-27.24%

ROE(5y)-74.05%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	105.25%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.31
Quick Ratio	8.31
Altman-Z	2.04

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)209.37%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-27.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-44.83%

EPS Next Y-30.95%

EPS Next 2Y-13.22%

EPS Next 3Y6.69%

EPS Next 5Y8.1%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-25.95%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-77.07%

EBIT Next 3Y-46.29%

EBIT Next 5Y-31.59%

FCF growth 1Y-41.83%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-41.91%

OCF growth 3YN/A

OCF growth 5YN/A

LANTERN PHARMA INC (LTRN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens